The stock of Chemed (NYSE:CHE, 30-year Financials) shows every sign of being fairly valued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher. At its current price of $465.7 per share and the market cap of $7.4 billion, Chemed stock shows every sign of being fairly valued. GF Value for Chemed is shown in the chart below.
Because Chemed is fairly valued, the long-term return of its stock is likely to be close to the rate of its business growth, which averaged 8.4% over the past three years and is estimated to grow 3.90% annually over the next three to five years.
Link: These companies may deliever higher future returns at reduced risk.
Investing in companies with poor financial strength has a higher risk of permanent loss of capital. Thus, it is important to carefully review the financial strength of a company before deciding whether to buy its stock. Looking at the cash-to-debt ratio and interest coverage is a great starting point for understanding the financial strength of a company. Chemed has a cash-to-debt ratio of 1.20, which is in the middle range of the companies in the industry of Healthcare Providers & Services. GuruFocus ranks the overall financial strength of Chemed at 8 out of 10, which indicates that the financial strength of Chemed is strong. This is the debt and cash of Chemed over the past years:
Investing in profitable companies carries less risk, especially in companies that have demonstrated consistent profitability over the long term. Typically, a company with high profit margins offers better performance potential than a company with low profit margins. Chemed has been profitable 10 years over the past 10 years. During the past 12 months, the company had revenues of $2.1 billion and earnings of $19.49 a share. Its operating margin of 18.99% better than 89% of the companies in the industry of Healthcare Providers & Services. Overall, GuruFocus ranks Chemed's profitability as strong. This is the revenue and net income of Chemed over the past years:
Growth is probably one of the most important factors in the valuation of a company. GuruFocus' research has found that growth is closely correlated with the long-term performance of a company's stock. If a company's business is growing, the company usually creates value for its shareholders, especially if the growth is profitable. Likewise, if a company's revenue and earnings are declining, the value of the company will decrease. Chemed's 3-year average revenue growth rate is in the middle range of the companies in the industry of Healthcare Providers & Services. Chemed's 3-year average EBITDA growth rate is 43.6%, which ranks better than 87% of the companies in the industry of Healthcare Providers & Services.
One can also evaluate a company's profitability by comparing its return on invested capital (ROIC) to its weighted average cost of capital (WACC). Return on invested capital (ROIC) measures how well a company generates cash flow relative to the capital it has invested in its business. The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. If the return on invested capital exceeds the weighted average cost of capital, the company is likely creating value for its shareholders. During the past 12 months, Chemed's ROIC is 25.03 while its WACC came in at 4.20. The historical ROIC vs WACC comparison of Chemed is shown below:
In conclusion, The stock of Chemed (NYSE:CHE, 30-year Financials) is believed to be fairly valued. The company's financial condition is strong and its profitability is strong. Its growth ranks better than 87% of the companies in the industry of Healthcare Providers & Services. To learn more about Chemed stock, you can check out its 30-year Financials here.
To find out the high quality companies that may deliever above average returns, please check out GuruFocus High Quality Low Capex Screener.
